Comparative effectiveness of bevacizumab and ranibizumab in the comparison of age-related macular degeneration treatments trials

Affiliations

Comment

Andrea Messori. JAMA Ophthalmol. 2015 Mar.

. 2015 Mar;133(3):363-4.

doi: 10.1001/jamaophthalmol.2014.4642.

¹ Health Technology Assessment Unit, Area Vasta Toscana Centro, Regional Health Service, Firenze, Italy.

No abstract available

Comment in

Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Ying GS, Maguire MG. Ying GS, et al. JAMA Ophthalmol. 2015 Jun;133(6):726. doi: 10.1001/jamaophthalmol.2015.0502. JAMA Ophthalmol. 2015. PMID: 25811288 Free PMC article. No abstract available.

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1. Ophthalmology. 2012. PMID: 22555112 Free PMC article. Clinical Trial.